Anti-CD20 Antibodies for Treatment of SLE-PAH
NCT05828147
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Systemic Lupus Erythematosus
Pulmonary Arterial Hypertension
Interventions
DRUG:
Rituximab
Sponsor
Chinese SLE Treatment And Research Group